1 VIDAS® TB-IGRA accuracy in tuberculosis patients and persons at varying risk of

2 exposure

- 3 Delia Goletti¹, Niaz Banaei², Rahul Batra³, Anne Emmanuelle Berger⁴, Azra Blazevic⁵, Elisabeth
- 4 Botelho-Nevers⁶, Ronan Breen³, Natalie Bruiners⁷, Emmanuelle Cambau⁸, Etienne Carbonnelle⁹,
- 5 Charles L. Daley¹⁰, Cécile Descotes-Genon¹¹, Francesco Di Gennaro¹², Florence Doucet-
- 6 Populaire¹³, Aliasgar Esmail¹⁴, Julia Dolores Estrada Guzman¹⁵, Luc Fontana¹⁶, Maria Laura
- 7 Gennaro⁷, Deborah Handler⁷, Rosa María Herrera Torres¹⁵, Daniel Hoft⁵, Nahed Ismail¹⁷,
- 8 Margaux Isnard¹¹, Alfred Lardizabal⁷, François Xavier Lesage¹⁸, Amanda Lopes¹⁹, Williams
- 9 Luciano López Vidal¹⁵, Rene Machado Contreras¹⁵, Philippe Manivet²⁰, Hubert Marotte²¹,
- 10 Frédéric Méchaï²², Amel Medjahed-Artebasse²³, Richard Meldau¹⁴, Yves Mérieux²⁴, Jacques
- 11 Morel²⁵, Faiza Mougari⁸, Suzette Oelofse¹⁴, Fabrizio Palmieri¹², Jean Luc Perrot²⁶, Elisa
- 12 Petruccioli¹, David T. Pride²⁷, Edouard Tuaillon²⁸, Caryn Upton²⁹, Naadira Vanker²⁹, Keertan
- 13 Dheda^{14,30}

- ¹Translational Research Unit, National Institute for Infectious Diseases L. Spallanzani-IRCCS, Rome,
- 16 Italy.
- 17 ²Stanford University School of Medicine, Stanford, CA, USA.
- ³Guy's and St Thomas' NHS Foundation Trust, London, UK.
- ⁴Laboratory of Immunology, University Hospital of Saint-Etienne, 42055 Saint-Etienne cedex 02, France.
- ⁵Saint Louis University School of Medicine, St. Louis, MO, USA.
- ⁶Infectious Diseases Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne cedex 02,
- France.
- ⁷Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
- ⁸APHP-GHU Nord Bichat Hospital, Service de mycobacteriologie specialisee et de reference, associate
- 25 laboratory of the National reference center for mycobacteria; Université Paris Cité IAME UMR1137
- 26 Inserm, 75018 Paris, France.
- ⁹Department of microbiology, Avicenne Hospital, Bobigny, France.
- ¹⁰Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA.
- 29 ¹¹Department of Infectious Diseases, Centre Hospitalier de Chambéry, Chambéry, France.
- 30 ¹²Respiratory Infectious Disease Unit Department, National Institute for Infectious Diseases L.
- 31 Spallanzani-IRCCS, Rome, Italy.
- 32 ¹³Department of Bacteriology-Hygiene, APHP Université Paris-Saclay, Antoine Beclere Hospital,
- 33 Clamart, France.
- 34 ¹⁴Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT
- 35 Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University
- of Cape Town, Cape Town, South Africa.
- 37 ¹⁵Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, 21000 Mexicali, B.C.,
- 38 Mexico.
- 39 ¹⁶Occupational and Environmental Health Department, University Hospital of Saint-Etienne, 42055 Saint-
- 40 Etienne cedex 02, France.

- 41 ¹⁷College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
- 42 ¹⁸Desbrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM, CHU, Montpellier,
- 43 France.
- 44 ¹⁹APHP-GHU Nord Lariboisiere Hospital, Service de Medecine interne, 75010 Paris, France.
- 45 ²⁰APHP GHU Nord Lariboisière Hospital, Centre de Ressources biologiques, 75010 Paris, France.
- 46 ²¹Université Jean Monnet, Rheumatology Department, CHU Saint-Etienne, INSERM, Mines Saint-
- 47 Etienne, 42055 Saint-Etienne cedex 02, France.
- 48 ²²Department of infectious diseases, Avicenne Hospital, Hôpitaux universitaires Paris Seine-Saint-Denis,
- 49 AP-HP, UFR SMBH, Université Sorbonne Paris Nord, Bobigny, France.
- 50 ²³CLAT 92, Anti-TB center of Nanterre, Nanterre, France.
- 51 ²⁴Etablissement Français du Sang Auvergne-Rhône-Alpes, Lyon, France.
- 52 ²⁵Department of Rheumatology, CHU and University of Montpellier, Phymedexp, University of
- Montpellier, Inserm, CNRS, Montpellier, France.
- 54 ²⁶Dermatology Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne cedex 02, France.
- 55 ²⁷University of California San Diego, La Jolla, CA, USA.
- 56 ²⁸Pathogenesis and Control of Chronic and Emerging Infections, INSERM U1058, University of
- 57 Montpellier, Montpellier University Hospital, Montpellier.
- 58 ²⁹TASK Applied Science, Cape Town, South Africa.
- 59 ³⁰Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School
- of Hygiene and Tropical Medicine, London, UK.

61

- 62 **Take-home message:** The first fully automated interferon-γ-release assay—the bioMérieux
- VIDAS® TB-IGRA—is highly specific and displays greater sensitivity than QuantiFERON®-TB
- 64 Gold Plus, and thus represents a valuable new and streamlined diagnostic tool for TB infection.

- ***Corresponding author:**
- 67 Prof. Keertan Dheda
- 68 Department of Medicine. H.46.41, Old Main Bldg. Groote Schuur Hospital, Observatory, Cape
- 69 Town, South Africa, 7925
- 70 Email: keertan.dheda@uct.ac.za

ABSTRACT

- 72 **Background:** Detection and treatment of individuals with presumed latent tuberculosis (TB)
- 73 infection (i.e., excluding active disease; LTBI) is imperative to achieve global TB control, as
- 74 they represent a potential transmission reservoir. However, more sensitive and user-friendly
- 75 diagnostic tools are needed.
- 76 **Methods:** We evaluated the accuracy for TB infection detection of the new VIDAS® TB-IGRA
- 77 (bioMérieux), a fully automated, single tube (thus eliminating the need for batch testing)
- overnight incubation assay, compared to the QuantiFERON®-TB Gold Plus (QFT-Plus,
- 79 QIAGEN), in a global multi-centre cross-sectional study (NCT04048018) that included patients
- with TB disease (n=200) or participants at varying levels of TB exposure (n=1460; mixed
- 81 exposure-risk-population).
- 82 **Results:** VIDAS® TB-IGRA identified TB disease with greater sensitivity than QFT-Plus
- 83 (97.5% vs. 80.7%, *P*<0.01%), and yielding significantly fewer false-negatives (2.5% vs. 17.5%;
- 84 P<0.01%) and indeterminate results (1.0% vs. 9.5%; P=0.02%). In the mixed exposure-risk-
- population, negative (NPA) and positive percent agreement (PPA) were 90.1% (1097/1217) and
- 92.1% (223/242), respectively. PPA increased with TB-exposure risk (up to 95.7% for high-risk
- participants), whereas NPA decreased (starting from 96.9% for low-risk participants).
- 88 Regression analyses revealed that VIDAS® TB-IGRA had a better fit with the risk-exposure
- gradient than the QFT-Plus. Specificity in extremely low TB-exposure risk participants (n = 125)
- 90 was high for both VIDAS® TB-IGRA and QFT-Plus (97.6% vs. 95.2%; P=8.33%).
- 91 **Conclusions:** VIDAS® TB-IGRA displayed greater sensitivity than QFT-Plus, had a lower
- 92 indeterminate rate, correlated better with an exposure gradient, and was highly specific,
- 93 suggesting that it is a potentially valuable tool for the diagnosis of LTBI.

INTRODUCTION

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

Tuberculosis (TB), due to infection by Mycobacterium tuberculosis (Mtb) is a significant global health problem that resulted in 1.3 million estimated deaths in 2022 [1]. TB is transmitted from person-to-person via bacteria-containing respiratory droplets [2]. The probability of being infected depends on the likelihood and degree of exposure, which is referred to as TB-exposure risk [3, 4]. Approximately 5–10% of Mtb-infected individuals develop TB disease (also called active TB); however, most infections (90–95%) are controlled by the host immune response and do not progress [2]. This asymptomatic non-transmissible state, known as latent TB infection (LTBI), can later progress to TB disease in response to triggers, such as impaired immune function, and represents an important reservoir for disease. Current research further suggests a continuum from exposure to disease, with transition between states dependent on modulators of host immunity [2, 5–9]. Hereafter the term TB infection is used to represent all stages of infection with M. tuberculosis without clinical manifestations of TB disease, as suggested in [10]. TB diagnosis remains challenging, particularly in middle/low-income countries. Furthermore, there is no gold-standard for the diagnosis of TB infection. Current methods -the tuberculin skin test (TST) and interferon (IFN)-γ-release assays (IGRAs) – assess host response to infection [9, 11-14] and neither can differentiate between TB disease and TB infection or predict risk of progression to TB disease. IGRAs, such as QuantiFERON-TB Gold Plus (QFT-Plus; QIAGEN) and T-SPOT-TB (Oxford Immunotec), are in vitro blood tests that measure T cell-mediated

release of IFN-y in response to synthetic Mtb complex-specific antigens (e.g., ESAT-6 and

CFP-10) [15]. These tests show enhanced specificity for *Mtb* relative to the TST and can be performed in a single patient visit.

Studies have shown the benefit of systematic testing and treatment for presumed TB infection in people with HIV, pulmonary-TB household contacts under-5 years old and groups at clinical risk for TB, including immigrants to low-burden settings, those receiving anti-tumour necrosis factor (TNF) treatment or dialysis, and organ-related or bone marrow transplant patients [16–18]. More recently, the World Health Organization (WHO) has advocated for TB infection screening and treatment of household contacts, even in TB-endemic settings, and modelling studies have indicated TB eradication will be impossible without treating the large reservoir of TB infection [19]. These findings highlight the importance of streamlined testing methods for TB infection. However, currently available IGRAs are often cumbersome to perform, requiring several steps and often the need for batch testing, which leads to complex laboratory workflows, introduces variability, and delays results [11, 12, 15, 20].

To address the unmet need for improved TB testing methods, bioMérieux developed the VIDAS® TB-IGRA, the first IGRA to be fully automated, from sample pipetting to result interpretation. This test, based on ESAT-6 and CFP-10 peptides-specific CD4+ and CD8+ T-cell responses [21] requires a single whole-blood sample per patient and provides results within 17 hours. Here, we assessed the accuracy for TB infection detection of VIDAS® TB-IGRA *vs.* QFT-Plus in an international, multi-centre, cross-sectional study of participants with culture-confirmed TB disease or with varying levels of TB-exposure risk (mixed exposure risk population). Since there is no gold standard to diagnose LTBI, sensitivity was evaluated in patients with TB disease and

specificity was evaluated in persons at extremely low TB risk. Figure 1 provides an overview of the study sub-groups and the performance characteristics.

141

142

139

140

METHODS

143 Study Design and Participants 144 Study participants were recruited, between December 2019 and December 2020, incorporating 145 i) the TB disease population, or ii) the mixed exposure risk population. The TB disease 146 population contained 200 culture-confirmed patients with TB disease recruited at 10 sites in both 147 low (France, Italy, UK, USA) and high TB-incidence countries (South Africa, Mexico). The 148 mixed exposure risk population contained 1,460 individuals recruited from 18 sites, with or 149 without identified risk factors for TB, and no history of TB disease or TB infection, as assessed 150 by questionnaire. See Supplementary Table S1 and Supplementary Figure S2 for more details on 151 study sites and participant flow, respectively. 152 The mixed exposure risk population was stratified in nine subgroups, along a gradient of TB-153 exposure risk, ranging from extremely low (blood-bank donors in France) to extremely high risk 154 (same-bedroom TB-case contacts). The subgroups were further pooled into aggregate low-, 155 medium-, and high-risk groups (Supplementary Table S2). 156 In this paper, the term TB infection is used to represent all stages of infection with Mtb without clinical manifestations of TB disease, as suggested in [10]. 157 158 Patients with TB disease were recruited within 15 days of TB treatment. TB disease was defined 159 as positive TB culture followed by Mtb-complex species identification. HIV-infected patients 160 were excluded. In addition, the following exclusion criteria applied to both populations: 161 treatment with TNF-α inhibitors within 3 months prior to enrolment, TST within 12 weeks prior

162 to enrolment, self-reported pregnancy, history of nontuberculous mycobacterial infection. Patient 163 demographic information is listed in table 1. 164 165 Written informed consent was obtained from all participants. Study protocols were approved by 166 Institutional Review Boards (IRB) or Independent Ethics Committees (IEC) as appropriate 167 (Supplementary Table S3). See supplementary information for the full list of study sites and site 168 staff. 169 170 Sample collection and testing Whole blood samples from each study participant were tested with the VIDAS® TB-IGRA 171 (bioMérieux, Marcy-l'Étoile, France) and QFT-Plus (QIAGEN, Hilden, Germany). Testing 172 173 procedures and result analysis followed the manufacturer's instructions. The VIDAS® TB-IGRA was performed with reagents and VIDAS® instruments provided by 174 175 bioMérieux. For this test, samples are loaded into the instrument with three stimulation reagents: 176 AG, antigen; MIT, mitogen (positive control); NIL, negative control. All steps are performed by the VIDAS®3 instrument, i.e., sample and reagent transfers, 37°C incubation for 16 hours, 177 automated enzyme-linked immunofluorescent assay (ELFA) to measure IFN-y. Qualitative 178 179 results are automatically determined using previously established thresholds (Supplementary 180 Table S4), notably 0.35 IU/mL for AG-NIL values. 181 182 Statistical analyses The rate of positive, negative or indeterminate results was calculated relative to the total number 183 184 of results for the population analysed, i.e., including indeterminate results. Statistical significance of differences between QFT-Plus and VIDAS® TB-IGRA was calculated using McNemar's test for paired data, with P<5% considered as significant.

For the TB disease population, sensitivity of QFT-Plus and VIDAS® TB-IGRA were independently calculated, excluding indeterminate results.

For the mixed exposure risk population, positive percent agreement (PPA) and negative percent agreement (NPA) of VIDAS® TB-IGRA relative to QFT-Plus were calculated, along with 95% confidence intervals (95% CIs). Study participants with indeterminate results from either test were not included in NPA/PPA computations. See Supplementary Methods for more information.

Logistic regression was performed to assess association between TB-exposure levels and positivity rates for individuals in the mixed exposure risk population (Table 5) considering: 1) the three aggregate risk groups (low, medium, and high) and 2) the three subgroups within the aggregate high-risk group (i.e., high-, very high-, and extremely high-risk subgroups). In each case, a univariate regression (unadjusted model) was performed. When necessary, the model was adjusted using three potential confounding variables that were present for all individuals and potentially related to TB infection: age, sex, and geographic area (defined as EU, US, or rest of world). For each variable, independence from exposure-risk level was first assessed using the Chi-square test for qualitative variables (sex and geographic area) and the Kruskal–Wallis Test for continuous variables (age), with α =1% for independence tests, before including it as a confounding factor in the model. This avoids sampling over-representation of some items in the

207 different exposure-risk levels. Results are reported as unadjusted and adjusted odds ratios (OR) 208 with 95% CIs. All statistical analyses were performed using SAS software v.9.4. 209 210 **RESULTS** 211 VIDAS® TB-IGRA showed superior sensitivity in the TB disease population In the TB disease population (200 culture-confirmed TB disease patients) the VIDAS® TB-IGRA 212 213 showed higher sensitivity compared to QFT-Plus (97.5% vs. 80.7% respectively, P<0.01%, see table 2). VIDAS® TB-IGRA significantly detected more TB disease cases than QFT-Plus (193 vs 214 215 146 among the 200 patients included in the analysis, i.e., 96.5% vs. 73.0%, P<0.01%), and led to 216 fewer false-negative (2.5% vs. 17.5%, P<0.01%) and indeterminate results (1.0% vs. 9.5%, P=0.02%). In summary, patients with TB disease were better identified by VIDAS® TB-IGRA as 217 218 compared to QFT-Plus. 219 220 Clinical performance of the VIDAS® TB-IGRA in the mixed exposure risk population 221 In the mixed exposure risk population (1,460 individuals without TB symptoms, at various levels of TB-exposure risk) the positivity rate was significantly higher for VIDAS® TB-IGRA than 222 223 QFT-Plus (23.5% vs. 16.6% respectively, *P*<0.01%, see table 2). NPA and PPA were 90.1% and 224 92.1%, respectively (table 3) indicating good agreement between the two tests. 225 226 Analysis of discrepant results in the mixed exposure risk population To better understand the agreement between VIDAS® TB-IGRA and QFT-Plus in the mixed 227 228 exposure risk population, we conducted two additional analyses.

We first evaluated whether discordant results were distributed around the cut-off of each test. We found they were distributed along the entire measuring interval, particularly when the VIDAS® TB-IGRA scored positive (Supplementary Figure S2). This indicates that discrepancies are not merely due to variability around the cut-off, and thus may result from other factors, such as different sensitivity of the tests. Next, we divided the mixed exposure risk population into nine subgroups ranked along a gradient from extremely-low to extremely-high TB-exposure risk. The subgroups may also be distributed into aggregate low-, medium-, and high-risk groups (Supplementary Table S2). Table 4 contains the VIDAS® TB-IGRA and QFT-Plus results for the subgroups and the aggregate groups. For both tests, the positivity rate increased with exposure risk, which is consistent with the expected likelihood for TB infection. However, the positivity rate was significantly higher for VIDAS® TB-IGRA vs. QFT-Plus in the aggregate medium- and high-risk groups, but not in the aggregate low-risk group (figure 2). NPA and PPA (VIDAS® TB-IGRA relative to QFT-Plus) varied along the risk gradient. As shown in figure 3 and Supplementary Table S5, PPA increased with the risk, whereas NPA decreased. For the aggregate low-, medium, high-risk groups, NPA was 96.9%, 92.2%, and 76.9%, respectively, while PPA was 61.5%, 85.7%, and 95.7%, respectively. Moreover, to assess association between exposure-risk level and test positivity, we performed the logistic regression analyses described in the Methods. Among possible confounding variables assessed for individuals within the three aggregate risk categories, only age showed independence from risk-exposure level (P=4.4% for age; P<0.01% for sex and area) and was therefore analysed by univariate logistic regression. For both tests, univariate odds of a positive

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

252 result were significantly associated with age (OR:1.01 [95%CI: 1.00, 1.02] for both tests; 253 P=1.0% and 2.2%, respectively), indicating that probability of a positive result increased by 1% 254 for each additional year of age. Age was therefore included as a covariate in both adjusted 255 models. 256 257 Adjusted and unadjusted ORs for individuals in different TB-exposure risk categories are shown in table 5 and Supplementary Figure S3. For the VIDAS® TB-IGRA, positivity rates of 258 259 individuals in aggregate medium- and high-risk categories were significantly higher than those in 260 the aggregate low-risk category, with unadjusted ORs of 2.54 [95%CI: 1.5, 4.29] and 20.11 261 [95%CI: 12.07, 33.49], respectively. This indicates that odds of a positive result with VIDAS® 262 TB-IGRA were 20.11 times higher for individuals in the high-risk vs. the low-risk category. For 263 QFT-Plus, only the positivity rate for individuals in the aggregate high-risk category was 264 significantly different from the aggregate low-risk category (unadjusted OR:17.7 [95%CI: 9.86, 265 31.79]). 266 267 Results for both tests were similar after adjusting for age; adjusted ORs for aggregate mediumand high-risk groups with VIDAS® TB-IGRA were 2.55 [95%CI: 1.51, 4.32] and 20.17 [95%CI: 268 269 12.1, 33.61], respectively, and adjusted OR for aggregate high-risk group with QFT-Plus was 270 17.7 [95%CI: 9.85, 31.81]. Collectively, these results show a better association between TB-271 exposure risk and positivity rate with VIDAS® TB-IGRA than QFT-Plus. 272 273 We next focused on the subgroups at high-, very high-, and extremely high-risk. For this 274 analysis, all potential cofounding variables (sex, geographic area, and age) showed independence

from exposure level (P=69.5% for sex; P=7.0% for area; P=32.5% for age). Univariate analyses revealed significant association between geographic area and positivity rate for both tests (P<0.01% for each test); sex was unrelated to positivity rate for both (P=12.3% for VIDAS® TB-IGRA; P=86.2% for QFT-Plus). Univariate odds of a positive result were also significantly associated with age for the VIDAS® TB-IGRA (OR:1.02 [95%CI: 1.00, 1.03], P=1.0%) but not the QFT-Plus (OR:1.01 [95%CI: 1.00, 1.02], P=16.5%). Consequently, age and geographic area were used as cofactors in the VIDAS® TB-IGRA adjusted model, whereas only area was included in the QFT-Plus adjusted model.

Adjusted and unadjusted ORs for the three highest subgroups are shown in table 5 and Supplementary Figure S4. Positivity rates for individuals in the extremely high-risk category were significantly different from those in the high-risk category with both the VIDAS® TB-IGRA and QFT-Plus, with unadjusted ORs of 2.64 [95%CI: 1.5, 4.65] and 2.07 [95%CI: 1.22, 3.5], respectively. However, significance for the QFT-Plus was lost after adjusting for geographic area (OR:1.72 [95%CI: 0.97, 3.03]), whereas for the VIDAS® TB-IGRA, the difference remained significant (OR:2.1 [95%CI: 1.13, 3.91]). These data suggest a better association between exposure and positivity rate for VIDAS® TB-IGRA among TB-case contacts.

Specificity in blood donors

We evaluated the specificity for TB infection detection by analysing the results obtained from blood donors recruited in Lyon, France (n=125), a low endemic area, with 5.7 new cases per 100,000 habitants in 2018 [22]. Because lifestyle and travel history of blood donors are

thoroughly analysed (to avoid any health risks for transfusion recipients) they are persons with the lowest TB-exposure risk level. For these individuals, specificity of the VIDAS® TB-IGRA and QFT-Plus was 97.6% and 95.2% (P=8.33%) respectively (table 2), with an NPA of 100% (95% CI: 96.9, 100.0) (Supplementary Table S5). These results indicate that VIDAS® TB-IGRA correctly identifies those not infected with Mtb and is therefore a high-specificity test for TB infection. Rate of indeterminate results Lastly, we compared the rate of indeterminate results for the entire study population (n=1660) obtained with each test and found that the VIDAS® TB-IGRA yielded significantly fewer indeterminate results than the QFT-Plus: 0.1% (2/1660) vs. 1.2% (20/1660), respectively, P=0.01%. This suggests the VIDAS[®] TB-IGRA may be valuable for patient management, as a lower frequency of indeterminate results will decrease the need for repeated testing. **DISCUSSION** In this study, we assessed the accuracy for TB infection detection of the newly developed VIDAS® TB-IGRA—the first fully automated IGRA—relative to the FDA-approved QFT-Plus, in an international cross-sectional study of culture-confirmed TB patients (TB disease population) or individuals at varying levels of TB-exposure risk (mixed exposure risk population). In the TB disease population, VIDAS® TB-IGRA showed greater sensitivity than QFT-Plus (97.5% vs. 80.7%, respectively) with fewer false-negative and indeterminate results. Notably, the QFT-Plus results are generally consistent with previous studies (11–27). The higher sensitivity of

298

299

300

301

302

303

304 305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

the VIDAS® TB-IGRA may be due to both the reagent design [21] and the full automation of the test.

In the mixed exposure risk population, VIDAS® TB-IGRA yielded a significantly higher positivity rate than QFT-Plus, with NPA and PPA values indicating good agreement between the tests. Then, to assess the accuracy, we stratified this cohort into subgroups with different levels of TB-exposure risk and analysed positivity along the exposure gradient. This is a useful strategy [10] in the absence of a test-based gold standard, as the infection probability depends on likelihood of *Mtb* exposure. For the subgroup at the lowest risk level—individuals expected to be negative—both VIDAS® TB-IGRA and QFT-Plus displayed high specificity. Conversely, for the subgroup at the highest TB-risk level—most likely to be infected—positivity rates for VIDAS® TB-IGRA and QFT-Plus were 71.4% and 55.7%, respectively. These results are consistent with the enhanced sensitivity of the VIDAS® TB-IGRA observed in the TB disease population. NPA and PPA values led to similar conclusions. At the extremes of the TB exposure gradient, both tests largely agree on the most likely result but disagree on the least likely result.

Logistic regression analysis shows that the odds of a positive result with VIDAS® TB-IGRA significantly increased with the risk of TB-exposure for individuals in aggregate medium- and high-risk groups relative to the aggregate low-risk group, even after adjusting for age. For QFT-Plus, only ORs in the aggregate high-risk group were significant (relative to the aggregate low-risk group) before and after adjustment. When focusing only on contact cases (aggregate-high group) we found that odds of a positive result for individuals at the extremely high-risk category were significantly higher than those in the high-risk category with both tests. However, for QFT-

Plus, significance was lost after adjusting for confounding variables. Thus, VIDAS® TB-IGRA may discriminate among persons at different levels of TB-exposure risk.

TB continues to pose a significant threat to public health, and reliable diagnostic methods are needed to support global TB control and eradication efforts [40]. The VIDAS® TB-IGRA represents the first test of its kind that is fully automated from sample input to results interpretation, thereby facilitating ease of use, saving time and improving laboratory workflows, while decreasing the possibility for human error and variability. Our data demonstrates that VIDAS® TB-IGRA has a higher sensitivity for TB infection detection compared to QFT-Plus—the most used IGRA worldwide—suggesting that this new assay can be a tool to improve current TB diagnostic capabilities.

A limitation of this study is that study participants were recruited from only two countries with high TB-incidence rates, South Africa and Mexico. However, the results obtained in this study are similar to those from a previous study [41] with, notably, 101 patients with TB disease from Burkina Faso (a high TB-incidence country) as well as France and the US, showing that VIDAS® TB-IGRA had consistently higher sensitivity than QFT-Plus, with fewer indeterminate results. Nevertheless, our study incorporated an international multi-centre design and inclusion of a large cohort of individuals at varying levels of TB-exposure risk, thereby allowing test evaluation over a wide exposure gradient. Future studies evaluating VIDAS® TB-IGRA accuracy in additional high-burden countries, ease of implementation, and better turnaround time in different operational settings are required.

In conclusion, our findings show that compared to the QFT-Plus, the VIDAS® TB-IGRA offers increased sensitivity and reliability (*i.e.*, fewer indeterminate results) for TB infection detection, without sacrificing specificity, thus representing a new and valuable tool in global efforts to end TB.

ACKNOWLEDGEMENTS

This work was funded by bioMérieux. We are grateful to all study participants. We thank all bioMérieux members who took part in this work. We are grateful to the bioMérieux Data

Science team for assisting with the statistical evaluation of the data, and the bioMérieux Clinical Affairs team for coordinating the study. The authors thank Laura Marinelli (BioScience Writers, USA) for providing medical writing support, which was funded by bioMérieux (Marcy L'Etoile,

France).

REFERENCES

- Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Licence: CC
 BY-NC-SA 3.0 IGO. .
- 2. Centers For Disease Control and Prevention. Tuberculosis Fact Sheets [Internet]. The Difference Between Latent TB Infection and TB Disease; 2019. Available from:
- https://www.cdc.gov/tb/publications/factsheets/general/ltbiandactivetb.htm.
- Aissa K, Madhi F, Ronsin N, Delarocque F, Lecuyer A, Decludt B, Remus N, Abel L,
 Poirier C, Delacourt C. Evaluation of a model for efficient screening of tuberculosis contact
 subjects. Am J Respir Crit Care Med United States; 2008; 177: 1041–1047.
- Acuña-Villaorduña C, Jones-López EC, Fregona G, Marques-Rodrigues P, Gaeddert M,
 Geadas C, Hadad DJ, White LF, Molina LPD, Vinhas S, Ribeiro-Rodrigues R, Salgame P,
 Palaci M, Alland D, Ellner JJ, Dietze R. Intensity of exposure to pulmonary tuberculosis
 determines risk of tuberculosis infection and disease. *European Respiratory Journal* [Internet] European Respiratory Society; 2018 [cited 2022 Apr 11]; 51Available from:
 https://erj.ersjournals.com/content/51/1/1701578.
- Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ,
 Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention
 strategies. *Nature Reviews Microbiology* 2009; 7: 845–855.
- Esmail H, Barry CE, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. *Drug Discovery Today* 2012; 17: 514–521.
- Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier
 E, Lewinsohn DM, Sherman DR. Incipient and Subclinical Tuberculosis: a Clinical Review
 of Early Stages and Progression of Infection. Clin Microbiol Rev 2018; 31.
- 402 8. Sousa J, Saraiva M. Paradigm changing evidence that alter tuberculosis perception and detection: Focus on latency. *Infection, Genetics and Evolution* 2019; 72: 78–85.
- Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. *Int J Infect Dis* 2022; S1201-9712(22)00126-6.
- 408 10. Framework for the evaluation of new tests for tuberculosis infection. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. .
- 410 11. Pai M, Behr M. Latent Mycobacterium tuberculosis Infection and Interferon-Gamma 411 Release Assays. *Microbiology Spectrum* 2016; 4.
- 412 12. Pai M, Sotgiu G. Diagnostics for latent TB infection: incremental, not transformative progress. *European Respiratory Journal* 2016; 47: 704–706.

- 414 13. Goletti D, Lee M-R, Wang J-Y, Walter N, Ottenhoff THM. Update on tuberculosis
- biomarkers: From correlates of risk, to correlates of active disease and of cure from disease.
- 416 Respirology 2018; 23: 455–466.
- 417 14. Kontsevaya I, Cabibbe AM, Cirillo DM, DiNardo AR, Frahm N, Gillespie SH, Holtzman
- D, Meiwes L, Petruccioli E, Reimann M, Ruhwald M, Sabiiti W, Saluzzo F, Tagliani E,
- Goletti D. Update on the diagnosis of tuberculosis. Clin Microbiol Infect 2023; : S1198-
- 420 743X(23)00340-3.
- 421 15. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ,
- 422 Cattamanchi A, Dowdy DW, Dheda K, Banaei N. Gamma interferon release assays for
- detection of Mycobacterium tuberculosis infection. *Clin Microbiol Rev* 2014; 27: 3–20.
- 16. Dheda K, van Zyl Smit R, Badri M, Pai M. T-cell interferon-gamma release assays for the
- rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden
- settings. Curr Opin Pulm Med United States; 2009; 15: 188–200.
- 427 17. Latent TB Infection: Updated and consolidated guidelines for programmatic management.
- 428 World Health Organization [Internet] 2019; Available from:
- https://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/.
- 430 18. Latent Tuberculosis Infection Resources [Internet]. CDC Latent Tuberculosis Infection
- Resources; 2020 [cited 2020 Feb 3]. Available from:
- https://www.cdc.gov/tb/publications/ltbi/ltbiresources.htm.
- 433 19. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. *Lancet* England; 2016; 387: 1211–
- 434 1226.
- 435 20. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi
- LA, Bateman ED, Dheda K. Within-subject variability and boosting of T-cell interferon-
- gamma responses after tuberculin skin testing. *Am J Respir Crit Care Med* United States;
- 438 2009; 180: 49–58.
- 439 21. Petruccioli E, Farroni C, Cuzzi G, Vanini V, Palmieri F, Vittozzi P, Goletti D. VIDAS(®)
- TB-IGRA reagents induce a CD4(+) and CD8(+) T-cell IFN-γ response for both TB
- infection and active TB. *Int J Tuberc Lung Dis* 2022; 26: 65–68.
- 442 22. Guthman J-P, Laporal S, Lévy-Bruhl D. La tuberculose maladie en France en 2018. Faible
- incidence nationale, forte incidence dans certains territoires et groupes de population. Bull
- 444 Epidémiol Head 2020; : 196–203.
- 23. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, Bergamini BM, D'Amico R,
- 446 Marchegiano P, Rumpianesi F, Fabbri LM, Richeldi L. Routine Hospital Use of a New
- Commercial Whole Blood Interferon-γ Assay for the Diagnosis of Tuberculosis Infection.
- 448 American Journal of Respiratory and Critical Care Medicine 2005; 172: 631–635.
- 449 24. Lee JY. Comparison of two commercial interferon- assays for diagnosing Mycobacterium
- 450 tuberculosis infection. European Respiratory Journal 2006; 28: 24–30.

- 451 25. Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W. Sensitivity Analysis and
- Potential Uses of a Novel Gamma Interferon Release Assay for Diagnosis of Tuberculosis.
- 453 *Journal of Clinical Microbiology* 2006; 44: 2844–2850.
- 454 26. Adetifa IM, Lugos MD, Hammond A, Jeffries D, Donkor S, Adegbola RA, Hill PC.
- Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium
- 456 tuberculosis infection and disease in The Gambia. BMC Infectious Diseases 2007; 7.
- 457 27. Dewan PK, Grinsdale J, Kawamura LM. Low Sensitivity of a Whole-Blood Interferon-γ
- Release Assay for Detection of Active Tuberculosis. *Clinical Infectious Diseases* 2007; 44:
- 459 69–73.
- 460 28. Mazurek GH, Weis SE, Moonan PK, Daley CL, Bernardo J, Lardizabal AA, Reves RR,
- Toney SR, Daniels LJ, LoBue PA. Prospective Comparison of the Tuberculin Skin Test and
- 2 Whole-Blood Interferon- Release Assays in Persons with Suspected Tuberculosis.
- 463 Clinical Infectious Diseases 2007; 45: 837–845.
- 464 29. Kanunfre KA, Leite OHM, Lopes MI, Litvoc M, Ferreira AW. Enhancement of Diagnostic
- Efficiency by a Gamma Interferon Release Assay for Pulmonary Tuberculosis. Clinical and
- 466 *Vaccine Immunology* 2008; 15: 1028–1030.
- 467 30. Ling DI, Pai M, Davids V, Brunet L, Lenders L, Meldau R, Calligaro G, Allwood B, Zyl-
- Smit R van, Peter J, Bateman E, Dawson R, Dheda K. Are interferon-γ release assays useful
- for diagnosing active tuberculosis in a high-burden setting? European Respiratory Journal
- 470 2011; 38: 649–656.
- 471 31. Danel C, Kabran M, Inwoley A, Badje A, Herrmann JL, Moh R, Lecarrou J, Gabillard D,
- Ntakpe JB, Deschamps N, Ouattara E, Perronne C, Eholie S, Anglaret X. Quantiferon-TB
- 473 Gold: Performance for Ruling out Active Tuberculosis in HIV-Infected Adults with High
- 474 CD4 Count in Côte d'Ivoire, West Africa. Goletti D, editor. *PLoS ONE* 2014; 9: e107245.
- 475 32. Xia H, Wang X, Li F, Longuet C, Vernet G, Goletti D, Zhao Y, Lagrange PH. Diagnostic
- 476 Values of the QuantiFERON-TB Gold In-Tube Assay Carried out in China for Diagnosing
- 477 Pulmonary Tuberculosis. Herrmann JL, editor. *PLOS ONE* 2015; 10: e0121021.
- 478 33. El Azbaoui S, Sabri A, Ouraini S, Hassani A, Asermouh A, Agadr A, Abilkassem R, Dini
- N, Kmari M, Akhaddar A, Laktati Z, Aieche S, El Hafidi N, Ben Brahim F, Bousfiha AA,
- 480 Ailal F, Deswarte C, Schurr E, Amar L, Bustamante J, Boisson-Dupuis S, Casanova JL,
- Abel L, El Baghdadi J. Utility of the QuantiFERON[®]-TB Gold In-Tube
- assay for the diagnosis of tuberculosis in Moroccan children. *The International Journal of*
- 483 *Tuberculosis and Lung Disease* 2016; 20: 1639–1646.
- 484 34. Boddu D, Verghese VP, Michael JS, Chacko A, Jeyaseelan V. Utility of the
- QuantiFERON-TB Gold In-tube test (QFT) compared with the Tuberculin Skin Test (TST)
- in diagnosing tuberculosis in Indian children with malnutrition: A prospective study.
- 487 *International Journal of Infectious Diseases* 2016; 45: 339.

- 488 35. Telisinghe L, Amofa-Sekyi M, Maluzi K, Kaluba-Milimo D, Cheeba-Lengwe M, Chiwele
- 489 K, Kosloff B, Floyd S, Bailey S-L, Ayles H. The sensitivity of the QuantiFERON®-TB
- Gold Plus assay in Zambian adults with active tuberculosis. The International Journal of
- 491 *Tuberculosis and Lung Disease* 2017; 21: 690–696.
- 492 36. Du F, Xie L, Zhang Y, Gao F, Zhang H, Chen W, Sun B, Sha W, Fang Y, Jia H, Xing A,
- Du B, Zheng L, Gao M, Zhang Z. Prospective Comparison of QFT-GIT and T-SPOT.TB
- 494 Assays for Diagnosis of Active Tuberculosis. *Scientific Reports* 2018; 8.
- 495 37. Kim YJ, Kang JY, Kim SI, Chang MS, Kim YR, Park YJ. Predictors for false-negative
- 496 QuantiFERON-TB Gold assay results in patients with extrapulmonary tuberculosis. *BMC*
- 497 Infectious Diseases [Internet] 2018 [cited 2021 Jul 28]; 18Available from:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131843/.
- 499 38. Hong JY, Park SY, Kim A, Cho S-N, Hur Y-G. Comparison of QFT-Plus and QFT-GIT
- tests for diagnosis of M. tuberculosis infection in immunocompetent Korean subjects.
- *Journal of Thoracic Disease* 2019; 11: 5210–5217.
- 39. Masood KI, Jamil B, Akber A, Hassan M, Islam M, Hasan Z. Testing for Mycobacterium
- tuberculosis infection using the QuantiFERON-TB GOLD assay in patients with comorbid
- 504 conditions in a tertiary care endemic setting. Tropical Diseases, Travel Medicine and
- 505 Vaccines 2020; 6.
- 506 40. World Health Organization Global Tuberculosis Report 2021 [Internet]. 2021 OctAvailable
- from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-
- 508 tuberculosis-report-2021.
- 509 41. Diagbouga S, Djibougou AD, Pease C, Alcaide A, Berthoux A, Bruiners N, Cirillo DM,
- Combary A, Falchero N, Handler D, Kabore A, Lardizabal A, Lopes A, Loubet M, Manivet
- P, Margain C, Meunier V, Mougari F, Onyuka A, Rivoiron S, Sagna T, Sanvert M,
- Sawadogo L, Simpore J, Cambau E, Gennaro ML. Preliminary diagnostic performance of
- the VIDAS® TB-IGRA for the detection of Mycobacterium tuberculosis infection and
- disease [Internet]. medRxiv; 2022 [cited 2022 Apr 22]. p. 2022.04.01.22271763Available
- from: https://www.medrxiv.org/content/10.1101/2022.04.01.22271763v1.

517 FIGURES




Figure 1. Overview of the study populations and the accuracy evaluated for VIDAS® TB-IGRA and QFT-Plus.




Figure 2. Positive results with VIDAS® TB-IGRA and QFT-Plus for participants in the aggregate low-, medium-, and high-risk groups in the mixed exposure risk population (excludes those with TB disease). ns: not significant; P-values calculated with the McNemar test are shown.




Figure 3. Negative percent agreement (NPA, top graph) and positive percent agreement (PPA, bottom graph) for the VIDAS® TB-IGRA relative to the QFT-Plus for participants in the aggregate low-, medium-, and high-risk groups in the mixed exposure risk population (excludes those with TB disease). Numbers reported next to the points correspond to the number of concordant samples divided by the number of participants in the aggregate group with negative (for NPA) or positive (for PPA) QFT-Plus result. As TB-exposure risk rises, NPA decreases and PPA increases. This indicates that at a low probability of infection, most participants negative by QFT-Plus were also negative by VIDAS® TB-IGRA (high NPA), whereas one-third of those positive by QFT-Plus were negative by VIDAS® TB-IGRA (lower PPA). Conversely, at high probability of infection, most participants positive by QFT-Plus were also positive by VIDAS® TB-IGRA (high PPA), whereas about one-fourth of those negative by QFT were positive by VIDAS® TB-IGRA (lower NPA). PPA and NPA values for all nine TB-exposure risk subcategories are shown in the Supplementary Table S5.

543 TABLES

544

547

548

549

550

TABLE 1. Demographic information for the participants enrolled in this study.

		TB disease population (n = 200)	Mixed exposure risk population (n = 1,460)	P-value *	
Gender	Female	57 (28.5%)	947 (64.9%)	c 0.010/	
Number (%)	Male	143 (71.5%)	513 (35.1%)	< 0.01%	
	IQR	19	23	0.03%	
Age	Median	31	35		
BCG-	Yes	132 (66.0%)	534 (36.6%)		
vaccinated Number (%)	No	16 (8.0%)	627 (42.9%)	< 0.01%	
	Unknown	52 (26.0%)	299 (20.5%)		
HIV-	Yes	N/A***	22 (1.5%)		
infected*** Number (%)	No	N/A***	1210 (82.9%)	N/A	
	Unknown	N/A***	228 (15.6%)		

^{*} TB disease and Mixed exposure risk populations were compared either with the Mann-Whitney test for Age, or with the Chi square test for Gender and BCG vaccination.

Abbreviations: BCG, bacille Calmette–Guérin; HIV, human immunodeficiency virus; IQR, interquartile range; N/A, Not Available.

^{**} HIV-positivity was an exclusion criterion for patients in the TB disease population.

TABLE 2. Results obtained with the VIDAS® TB-IGRA and QFT-Plus tests for the TB disease and mixed exposure risk populations, as well as the blood donor subgroup at extremely low risk for TB. Percentages are shown in brackets while 95% Confidence Intervals are shown in square brackets.

	TB disease population (n = 200)				
	VIDAS® TB-IGRA QFT-Plus		P-value**		
True Positive	193 (96.5%)	146 (73.0%)	<0.01%		
False Negative	5 (2.5%)	35 (17.5%)	<0.01% 0.02%		
Indeterminate	2 (1.0%)	19 (9.5%)			
Sensitivity* [95%CI]	97.5% (193/198) [94.2, 99.2]%				
	Mixed exposure risk population $(n = 1,460)$				
	VIDAS® TB-IGRA	QFT-Plus	P-value**		
Positive	343 (23.5%)	242 (16.6%)	<0.01%		
Negative	1,117 (76.5%)	1,217 (83.4%)	<0.01%		
Indeterminate	0 (0.0%)	1 (0.1%)	NC		
	Extremely Low Ris	k Subgroup / Blood Don	ors $(n = 125)$		
	VIDAS® TB-IGRA	QFT-Plus	<i>P</i> -value		
Positive	3 (2.4%)	6 (4.8%) NC			
Negative	122 (97.6%)	119 (95.2%)	8.33% (NS)		
Indeterminate	0 (0.0%)	0 (0.0%)	NA		
Specificity [95%CI]	97.6% (122/125) [93.1, 99.5]%	95.2% (119/125) [89.8, 98.2]%	8.33% (NS)		

^{*} Excluding indeterminate results.

Abbreviations: CI, confidence interval. NA, not applicable. NC, not calculated. NS, non-significant. QFT-Plus, QuantiFERON-TB Gold Plus.

^{**} Unless otherwise stated, the McNemar's test for paired data was used, comparing the results identified on the row with all other results, e.g., for the first row: True Positive vs (False Negative + Indeterminate).

^{***} Calculated using the Bowker's Symmetry Test.

TABLE 3. Negative percent agreement (NPA) and positive percent agreement (PPA) for the VIDAS® TB-IGRA relative to the QFT-Plus test for participants in the mixed exposure risk population.

	QFT-Plus			
Mixed exposure risk population		Negative	Positive	Total*
	Negative	1097	19	1116
VIDAS® TB-IGRA	Positive	120	223	343
	Total*	1217	242	1459
NPA* [95%CI]	90.1% [88.3; 91.7]%			
PPA* [95%CI]	92.1% [88.1; 94.9]%			

^{*}Excluding indeterminate results.

Abbreviations: CI, confidence interval; QFT-Plus, QuantiFERON-TB Gold Plus.

TABLE 4. VIDAS® TB-IGRA and QFT-Plus test results for individuals within each subgroup of
 the mixed exposure risk population.

TD Evnosure	Participants (n)	Number of Negation	ve Results (%)	Number of Positive Results (%)		
TB-Exposure Risk		VIDAS® TB- IGRA	QFT-Plus	VIDAS® TB- IGRA	QFT-Plus	
Extremely Low	125	122 (97.6%)	119 (95.2%)	3 (2.4%)	6 (4.8%)	
Very Low	90	80 (88.9%)	84 (93.3%)	10 (11.1%)	6 (6.7%)	
Low	118	113 (95.8%)	117 (99.2%)	5 (4.2%)	1 (0.8%)	
Aggregate Low	333	315 (94.6%)	320 (96.1%)	18 (5.4%)	13 (3.9%)	
Medium Low	598	553 (92.5%)	593 (99.2%)	45 (7.5%)	5 (0.8%)	
Medium	13	12 (92.3%)	13 (100.0%)	1 (7.7%)	0 (0.0%)	
Medium High	68	28 (41.2%)	31 (45.6%)	40 (58.8%)	37 (54.4%)	
Aggregate Medium	679	593 (87.3%)	637 (93.8%)	86 (12.7%)	42 (6.2%)	
High	296	152 (51.4%)	184 (62.2%)	144 (48.6%)	112 (37.8%)	
Very High	81	36 (44.4%)	45 (55.6%)	45 (55.6%)	36 (44.4%)	
Extremely High	70	20 (28.6%)	31 (44.3%)	50 (71.4%)	39 (55.7%)	
Aggregate High	447	208 (46.5%)	260 (58.2%)	239 (53.5%)	187 (41.8%)	

Abbreviations: QFT-Plus, QuantiFERON-TB Gold Plus.

TABLE 5. Univariate and multivariate odds ratios determined by logistic regression for participants at different levels of TB exposure risk.

VIDAS® TB-IGRA			QFT-Plus				
Risk group	n	Positive Results (%)	Unadjusted OR [95%CI]*	Adjusted OR [95% CI]**	Positive Results (%)	Unadjusted OR [95% CI]	Adjusted OR [95% CI]**
Aggregate Low	333	18 (5.4%)	1	1	13 (3.9%)	1	1
Aggregate Medium	679	86 (12.7%)	2.54 [1.50, 4.29]	2.55 [1.51, 4.32]	42 (6.2%)	1.62 [0.86, 3.07]	1.63 [0.86, 3.08]
Aggregate High	447	239 (53.5%)	20.11 [12.07, 33.49]	20.17 [12.10, 33.61]	187 (41.8%)	17.70 [9.86, 31.79]	17.70 [9.85, 31.81]
Risk subgroup	n	Positive Results (%)	Unadjusted OR [95%CI]	Adjusted OR [95% CI]***	Positive Results (%)	Unadjusted OR [95% CI]	Adjusted OR [95% CI]****
High	296	144 (48.6%)	1	1	112 (37.8%)	1	1
Very High	81	45 (55.6%)	1.32 [0.81, 2.16]	1.50 [0.86, 2.59]	36 (44.4%)	1.31 [0.80, 2.16]	1.45 [0.84, 2.49]
Extremely High	70	50 (71.4%)	2.64 [1.50, 4.65]	2.10 [1.13, 3.91]	39 (55.7%)	2.07 [1.22, 3.50]	1.72 [0.97, 3.03]

^{568 *}Significant associations are shown in bold.

566

567

^{569 **}Adjusted for age of study participants.

^{570 ***}Adjusted for age of study participants and geographic area (defined as EU, US, or rest of world).

^{571 ****}Adjusted for geographic area.

⁵⁷² Abbreviations: CI, confidence interval; OR, odds ratio; QFT-Plus, QuantiFERON Plus.